Years after Pfizer merger, ex-Medivation exec gets insider trading charge
insider trading, Legal, litigation, M&A, Matthew Panuwat, Medivation, Pfizer
0 Comment
Medivation
Why does UK biotech struggle to generate leaders?
biotech business, David Hung, Medivation, UK biotech, UK life sciences
0 Comment
Can the UK emulate America’s culture of biotech entrepreneurship?
Takeda earmarks $15 billion for M&A – reports
M&A, Medivation, Takeda
0 Comment
Japanese company could be on the acquisition trail.
Medivation deal could spark biotech M&A
Biotech, Celgene, M&A, Medivation, Pfizer, Sanofi
0 Comment
Sanofi criticised following failure of Medivation bid.
Pfizer confirms $14bn Medivation merger
Medivation, Pfizer, Prostate cancer, Sanofi, Xtandi
0 Comment
Drug giant confirms press reports.
Merck, Pfizer and Gilead all interested in Medivation buy-out
Celgene, Gilead, Medivation, Merck, Pfizer, Sanofi
0 Comment
Sanofi has competition in its bid to acquire cancer specialist
Medivation cancer drug ‘best in class’ – CEO
cancer, Celgene, Medivation, Pfizer, R&D, Sanofi
0 Comment
Sanofi interested in PARP inhibitor talazoparib.
Medivation in merger talks with Sanofi and others
breast, cancer, Celgene, M&A, Medivation, Pfizer, prostate, Sanofi
0 Comment
Sources say Pfizer and Celgene are also interested.
Sanofi pushes on with Medivation takeover attempt
cancer, M&A, Medivation, Oncology, prostate, Sanofi
0 Comment
French firm is attempting to oust Medivation’s board.
1 2